ubiquitinspecif
proteas
belong
famili
deubiquitinas
rescu
protein
target
proteasom
degrad
revers
ubiquitin
variou
cancer
includ
prostat
cancer
ovarian
carcinoma
upregul
lead
increas
level
deubiquitin
substrat
fatti
acid
synthas
cyclin
auroraa
thu
play
critic
role
tumor
cell
surviv
therefor
repres
therapeut
target
leukemia
drug
found
potent
inhibitor
enzymekinet
xray
crystallograph
data
suggest
display
noncompetit
slowbind
inhibitori
mechan
studi
provid
clear
rational
clinic
evalu
cancer
ubiquitin
kind
posttransl
modif
well
deubiquitin
togeth
compris
ubiquitin
system
regul
turnov
cellular
protein
also
variou
mode
monoor
polyubiquitin
receptor
traffick
dna
repair
cellcycl
progress
immun
respons
autophagi
apoptosi
versatil
rais
interest
pinpoint
compon
ubiquitin
system
prime
candid
drug
target
among
pursuit
deubiquitinas
dub
pharmaceut
target
still
infanc
inhibitor
enter
clinic
trial
albeit
broadspectrum
inhibitor
patent
highli
select
inhibitor
develop
human
genom
encod
dub
largest
five
dub
famili
ubiquitinspecif
proteas
usp
one
abl
remov
ubiquitin
rang
protein
substrat
fatti
acid
synthas
cyclin
auroraa
fatti
acid
synthas
report
highli
express
varieti
cancer
includ
cancer
prostat
ovari
lung
colon
breast
cyclin
auroraa
play
critic
role
regul
cell
cycl
progress
mitot
event
respect
studi
suggest
inhibit
may
good
therapeut
approach
cancer
davi
et
al
report
small
molecul
induc
cell
cycl
arrest
inhibit
growth
colorect
mantl
cell
lymphoma
cell
line
via
inhibit
albeit
still
clinic
drug
present
studi
old
drug
still
clinic
use
treat
leukemia
rheumatoid
arthriti
bowel
diseas
identifi
potent
inhibitor
studi
use
enzym
kinet
xray
crystallographi
delin
direct
bind
perform
find
support
earlier
result
suggest
broad
spectrum
activ
implic
respect
need
direct
clinic
evalu
use
cancer
identif
inhibitor
human
accord
previou
studi
involv
molecular
dock
experi
antileukemia
immunosuppress
drug
act
inhibitor
sar
mer
coronaviru
papainlik
proteas
plpro
may
also
abl
bind
activ
site
human
kind
enzym
share
palmthumbfing
structur
scaffold
conserv
catalyt
triad
cyshisaspasn
valid
simul
result
deubiquitin
activ
recombin
human
catalyt
domain
residu
measur
presenc
variou
concentr
publish
xx
xx
xxxx
open
wwwnaturecomscientificreport
scientif
report
tabl
interestingli
show
signific
inhibitori
effect
ic
fig
b
wherea
compound
inhibit
coronavir
plpro
ic
first
demonstr
besid
serv
antileukemia
drug
might
also
effect
chemotherapeut
agent
cancer
depend
upregul
similar
concept
address
davi
et
al
use
strategi
highthroughput
screen
chemic
medicin
optim
identifi
sulfamidobenzamid
deriv
ic
tabl
result
growth
arrest
sever
kind
cancer
cell
howev
clinic
medicin
yet
detail
inhibit
mechan
still
unclear
protein
concentr
held
assay
perform
mm
phosphat
ph
repeat
ensur
reproduc
symbol
bar
repres
mean
standard
error
respect
solid
line
repres
best
global
fit
noncompetit
inhibit
equat
r
sqr
kinet
paramet
best
fit
shown
tabl
scientif
report
doi
inhibit
mechan
understand
detail
kinet
mechan
involv
interact
deubiquitin
activ
enzym
measur
variou
combin
inhibitor
concentr
ubafc
substrat
concentr
inhibit
data
global
fit
possibl
kinet
model
includ
competit
noncompetit
uncompetit
mix
inhibit
model
interestingli
result
suggest
noncompetit
inhibit
pattern
best
describ
inhibit
doubl
reciproc
plot
show
line
intercept
xaxi
k
fig
tabl
hand
although
also
show
noncompetit
inhibit
pattern
k
inhibit
higher
tabl
k
inhibit
higher
k
deubiquitin
reaction
wherea
inhibit
higher
k
deubiquitin
reaction
latter
k
valu
indic
ineffect
inhibit
contrast
show
competit
inhibit
pattern
coronavir
plpro
although
inhibitor
chalconebas
small
molecul
discov
complex
structur
yet
solv
moreov
noncompetit
inhibitor
may
show
benefit
combin
adjuv
treatment
competit
inhibitor
interest
valid
bind
mode
therefor
tri
determin
structur
complex
xray
crystallographi
although
repeat
attempt
crystal
complex
fail
final
succeed
crystal
complex
ub
soak
crystal
presenc
crystal
structur
complex
determin
resolut
tabl
fig
fortun
residu
electron
densiti
like
molecul
lie
one
side
catalyt
triad
ub
locat
opposit
side
fig
extend
data
fig
residu
electron
densiti
like
place
refin
use
diffract
data
without
soak
howev
refin
temperatur
factor
higher
protein
decreas
occup
lower
temperatur
factor
molecul
indic
may
exist
full
half
occup
asymmetr
unit
tri
increas
soak
concentr
soak
time
enhanc
occup
electron
densiti
fail
cocrystal
protein
also
fail
nevertheless
structur
indic
polar
interact
residu
van
der
waal
contact
nearbi
residu
may
also
show
possibl
coval
bond
interact
sulfur
atom
thiol
group
residu
fig
unlik
lack
amid
group
tabl
may
explain
ineffect
hydrogenbond
interact
amid
sidechain
oxygen
atom
residu
overal
ternari
complex
structur
suggest
exist
enzymesubstrateinhibitor
esi
complex
confirm
noncompetit
mechan
inhibit
structur
comparison
human
complex
without
partial
occup
complex
structur
conform
chang
due
ligand
bind
use
evalu
bind
effect
compar
activ
site
presenc
absenc
fig
interestingli
bind
lead
movement
loop
residu
result
shift
residu
toward
previou
studi
suggest
absolut
conserv
residu
usp
play
dual
role
oxyanion
hole
format
maintain
correct
align
proton
catalyt
compet
although
direct
interact
tabl
kinet
paramet
inhibit
human
via
deubiquitin
assay
presenc
appar
kinet
paramet
determin
best
fit
data
noncompetit
inhibit
model
eq
r
sqr
respect
b
k
inact
determin
best
fit
data
satur
equat
c
inhibitor
ic
valu
davi
et
al
crystal
structur
complex
accordingli
movement
residu
follow
bind
also
result
inhibit
besid
present
structur
carboxyl
group
polar
interact
residu
fig
differ
may
due
chang
free
thiol
group
disulfid
less
neg
less
electrostat
repuls
carboxyl
group
earlier
studi
structur
wildtyp
complex
ub
show
misorient
thiol
group
due
electrostat
repuls
residu
carboxyl
group
resolv
present
studi
crystal
structur
mutant
complex
ub
determin
resolut
tabl
inde
hydroxyl
group
show
orient
chang
compar
thiol
group
fig
chang
result
rescu
hydrogenbond
interact
reconnect
catalyt
triad
even
presenc
ub
interestingli
surprisingli
mutant
still
maintain
deubiquitin
activ
fig
indic
mutant
less
activ
fulli
inact
furthermor
presenc
dub
activ
mutant
decreas
suggest
still
inhibit
enzym
without
disulfidebond
interact
compar
wildtyp
residu
interact
conform
chang
mutant
indic
exist
bind
pocket
fig
movement
residu
follow
bind
may
also
result
inhibit
mutant
moreov
present
structur
one
oxygen
atom
carboxyl
group
locat
oxyanion
hole
consist
three
amid
fig
previou
studi
indic
mutat
residu
influenc
kinet
paramet
k
cat
k
indic
two
mainchain
amid
residu
enough
stabil
oxyanion
format
catalysi
hand
differ
complex
complex
show
electrostat
interact
residu
fig
suggest
may
directli
influenc
proton
via
interact
overal
present
structur
provid
foundat
understand
molecular
basi
catalysi
slowbind
inhibit
accord
ternari
structur
enzym
may
covalentbond
interact
albeit
show
partial
occup
fig
although
rare
disulfidebond
format
confirm
van
der
vli
et
al
overal
structur
fragment
cyan
complex
ubiquitin
yellow
orang
structur
residu
dash
line
miss
zinc
ion
coordin
four
cystein
residu
shown
grey
sphere
catalyt
triad
final
six
ctermin
residu
ub
shown
stick
b
stereo
view
activ
site
omit
f
f
c
electrondens
map
contour
shown
green
mesh
improv
omit
map
qualiti
polder
map
grey
mesh
exclud
bulk
solvent
contour
gener
use
phenix
dash
line
indic
hydrophil
interact
ub
one
catalyt
triad
residu
disulfid
bond
interact
structur
figur
paper
produc
use
pymol
http
wwwpymolorg
scientif
report
present
studi
valid
revers
enzym
inactiv
incub
mm
h
follow
remov
small
molecul
use
sephadex
column
treatment
led
loss
activ
suggest
irrevers
inhibit
irrevers
inhibit
enzym
activ
indic
may
coval
associ
enzym
next
incub
mm
min
measur
activ
see
reactiv
although
high
enzym
activ
restor
treat
respect
rescu
effect
reduct
suggest
modif
may
due
disulfid
bond
interact
enzym
nevertheless
observ
suggest
may
slowbind
inhibitor
measur
timeresolv
emiss
variou
concentr
found
emiss
curv
curv
downward
indic
slowbind
mechan
fig
differ
k
inact
variou
concentr
determin
fit
data
eq
plot
versu
variou
concentr
fig
satur
pattern
irrevers
inhibit
enzym
activ
suggest
slow
bind
may
due
affin
label
accord
copland
model
follow
fit
data
satur
equat
obtain
k
inact
fig
tabl
valu
even
lower
k
indic
may
undergo
covalentbond
interact
soon
bind
found
noncompetit
inhibit
human
also
show
slowbind
inhibitori
effect
enzym
kinet
catalyt
mechan
confirm
xray
crystallographi
ternari
complex
structur
interpret
enzymesubstrateinhibitor
complex
suggest
alloster
bind
inhibitor
substrat
enzym
bind
also
lead
movement
absolut
conserv
residu
play
essenti
role
catalysi
explain
bind
inhibit
final
irrevers
inhibit
enzym
inhibitor
slowbind
inhibit
via
affin
label
suggest
possibl
coval
bond
interact
residu
find
reveal
broad
spectrum
activ
provid
biochem
structur
evid
evalu
possibl
applic
clinic
combin
treatment
cancer
plasmid
construct
cdna
human
gene
id
catalyt
domain
residu
amplifi
polymeras
chain
reaction
primer
use
mgc
premier
cdna
clone
id
templat
pcr
product
digest
nheixhoi
insert
vector
tag
cterminu
novagen
primer
sequenc
sitedirect
mutagenesi
mutant
read
frame
plasmid
verifi
dna
sequenc
express
purif
human
present
studi
use
catalyt
domain
residu
sinc
fulllength
obtain
despit
effort
express
fulllength
protein
sumofus
strategi
clone
plasmid
transform
escherichia
coli
rosetta
cell
novagen
cultur
l
lb
medium
kanamycin
chloramphenicol
grown
h
incub
h
ad
mm
thiogalactopyranosid
centrifug
cell
pellet
resuspend
lysi
buffer
mm
tri
ph
mm
nacl
glycerol
triton
mm
sonic
centrifug
g
elut
buffer
contain
mm
tri
ph
mm
nacl
mm
imidazol
mm
next
protein
load
onto
gelfiltr
column
ge
healthcar
use
run
buffer
mm
sodium
phosphat
ph
mm
nacl
mm
dithiothreitol
puriti
collect
fraction
check
sdspage
protein
concentr
use
amicon
kda
filter
millipor
final
purifi
protein
mgml
glycerol
flashfrozen
liquid
nitrogen
store
typic
yield
protein
mg
wildtyp
mg
mutant
per
liter
cell
cultur
deubiquitin
assay
steadyst
kinet
analys
deubiquitin
assay
perform
mm
phosphat
buffer
ph
concentr
fluorogen
substrat
ubiquitin
ubafc
boston
biochem
vari
concentr
catalyt
domain
mutant
held
enzym
activ
measur
continu
monitor
fluoresc
emiss
increas
nm
upon
substrat
cleavag
excit
wavelength
nm
perkinelm
ls
luminesc
spectromet
increas
fluoresc
linear
first
kinet
paramet
obtain
fit
initi
veloc
v
michaelismenten
equat
program
sigmaplot
systat
softwar
use
data
analysi
inhibit
assay
concentr
substrat
ubafc
inhibitor
vari
concentr
catalyt
domain
held
inhibit
data
inhibitor
found
best
fit
noncompetit
inhibit
model
accord
v
steadyst
veloc
k
inact
appar
firstord
rate
constant
interconvers
v
v
time
ub
sigmaaldrich
obtain
sittingdrop
vapordiffus
method
incub
overnight
mixtur
mgml
molar
ratio
crystal
reservoir
solut
consist
peg
mgcl
bistri
ph
mixtur
crystal
solut
peg
tacsim
ph
singl
diamondshap
crystal
mm
size
grew
week
crystal
soak
reservoir
solut
supplement
mm
h
flashcool
liquid
nitrogen
xray
data
collect
structur
determin
refin
xray
diffract
data
collect
k
beamlin
nation
synchrotron
radiat
research
center
taiwan
roc
use
adsc
rayonix
ccd
detector
xray
wavelength
imag
data
process
scale
packag
kind
crystal
belong
space
group
cell
dimens
crystal
b
c
b
c
crystallograph
asymmetr
unit
contain
one
catalyt
domain
one
ub
structur
solv
molecular
replac
method
phaser
use
structur
pdb
code
model
structur
refin
carri
use
refmac
atom
model
built
use
coot
access
code
final
structur
inform
deposit
protein
data
bank
pdb
code
respect
